Ozmosi | BAY 86-5277 Drug Profile
Contact Us
Drug Search Results
Using advanced filters...
Advanced Search [+]

BAY 86-5277

Alternative Names: bay 86-5277, bay 86 5277, bay 865277
Clinical Status: Active
Latest Update: None
Latest Update Note: None

Product Description

BAY 86-5277 is a CCR-1 inhibitor drug candidate being used to treat patients with COVID-19 and need for additional respiratory support. (Sourced from: https://www.hidih.org/projects/catcovid)

Mechanisms of Action: CCR1 Antagonist

Novel Mechanism: Yes

Modality: Unknown

Route of Administration: N/A

FDA Designation: *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Charité – Universitätsmedizin Berlin
Company Location: Europe
Company CEO:
Additional Commercial Interests: None

Clinical Description

Countries in Clinic:

Active Clinical Trial Count: 1

Recent & Upcoming Milestones

Highest Development Phases

Phase 2: Acute Respiratory Distress Syndrome|COVID-19

Trial ID

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

Latest Trial Update Date

Data Updated

2021-000613-16

 CATCOVID

P2

Active, not recruiting

COVID-19|Acute Respiratory Distress Syndrome

2022-11-29

Recent News Events

Date

Type

Title

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you've used PRYZM, we hope you're able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions